SecBot SecBot
SECBOTREPLAY Home › Report › MESO

MESO · Mesoblast received a BLA filing number from the FDA and requested a…

MESOBLAST LTD · 6-K filed Jun 30, 2026 at 20:50 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jun 30, 2026 at 20:50 ET

Mesoblast received a BLA filing number from the FDA and requested a modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. The drug has Orphan Drug and RMAT designations, and the company highlighted recent FDA guidance on regulatory flexibility for orphan rare diseases. This is a positive regulatory milestone but does not guarantee approval.

  • Received BLA filing number from FDA for rexlemestrocel-L in end-stage heart failure with LVADs
  • Requested modular review of the BLA
  • Rexlemestrocel-L has Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations
  • FDA recently issued draft guidance on flexibility for demonstrating substantial evidence of effectiveness for orphan rare diseases

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access